Core Insights - The company faced challenges in Q2 2026, with significant revenue and earnings declines compared to the previous year, primarily due to increased competition in the GLP-1 market following the launch of the MINDBODY system [1][4][13] - Despite these challenges, the company is optimistic about long-term growth, particularly through the integration of the LoveBiome acquisition and the launch of new products [6][10][11] Financial Performance - Q2 2026 net revenue was $48.9 million, down 27.8% from $67.8 million in Q2 2025, but up 2.9% sequentially from Q1 2026 [13][14] - Sales of the MINDBODY GLP-1 system decreased by $16.2 million compared to the prior year, while the LoveBiome product line contributed $4.1 million in revenue [13][14] - Gross profit percentage for Q2 was 74%, down from 80.5% in the prior year, primarily due to a one-time inventory reserve related to MINDBODY [15][18] Market Dynamics - The competitive landscape for GLP-1 products has shifted, with pharmaceutical options becoming more accessible and affordable, impacting the sales of the MINDBODY system [5][6] - The company is recognizing a reserve against a portion of its GLP-1 inventory to respond to these changing dynamics [6][18] Product Development and Launches - The integration of LoveBiome has led to operational synergies and the launch of new products, including Axila X and Phytopower B, which are expected to drive engagement and diversify the product portfolio [7][8][10] - The company is also focusing on the HealthyEdge stack, which combines Protandim NRS-2 with P84, as a key enrollment product for consultants [9][40] Strategic Initiatives - The company is modernizing its technology infrastructure through a partnership with Shopify, aiming to enhance e-commerce capabilities and improve customer experience [9][46][47] - A new $60 million share repurchase program has been authorized, reflecting the company's commitment to returning capital to shareholders [11][20] Future Outlook - The company expects revenue for fiscal 2026 to be in the range of $185 million to $200 million, with adjusted EBITDA of $15 million to $19 million [20][21] - The anticipated growth is supported by the positive momentum from the LoveBiome integration and upcoming product launches [21][54]

Financial Data and Key Metrics Changes - For Q2 of fiscal 2026, net revenue was $48.9 million, down 27.8% from $67.8 million in Q2 of fiscal 2025, but up 2.9% sequentially from Q1 [14] - The decline was primarily driven by a $16.2 million decrease in sales of the MindBody GLP-1 System, partially offset by $4.1 million in revenue from the LoveBiome product line [14] - Gross profit percentage decreased to 74% from 80.5% in the prior year, reflecting a one-time inventory obsolescence allowance [15] - GAAP net income was $0.3 million, or $0.02 per diluted share, compared to $2.6 million, or $0.19 per diluted share in the prior year [17] Business Line Data and Key Metrics Changes - Sales of the MindBody GLP-1 System significantly declined due to increased competition from pharmaceutical options, which have become more accessible and affordable [5][6] - The LoveBiome acquisition contributed $4.1 million in revenue, with two new products launched that are expected to drive engagement and growth [8][9] Market Data and Key Metrics Changes - Revenue in the Americas decreased 32.6% to $38.5 million, while Asia-Pacific and Europe revenue decreased 2.1% to $10.4 million [15] - The Americas decline was attributed to a 25.2% decrease in total active accounts, primarily from the customer base [15] Company Strategy and Development Direction - The company is focused on stabilizing the GLP-1 business and exploring cost reduction opportunities while remaining committed to the MindBody GLP-1 System [7] - The integration of LoveBiome is seen as a strategic move to diversify the product portfolio and enhance market growth [8][11] - The company is modernizing its technology infrastructure through a partnership with Shopify to improve e-commerce capabilities and customer experience [10][40] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that Q2 performance did not meet expectations but expressed optimism about long-term growth in the health and wellness ecosystem [4] - The company expects revenue for fiscal 2026 to be in the range of $185 million to $200 million, with adjusted EBITDA of $15 million to $19 million [19] - Management believes the competitive dynamics in the GLP-1 market can be navigated due to the unique value proposition of their natural solutions [47] Other Important Information - The company announced a new $60 million share repurchase program and a quarterly cash dividend of $0.045 per share [18][19] - The CEO announced plans for retirement in April 2026, with a succession plan in place to ensure leadership continuity [20] Q&A Session Summary Question: What was the cash transaction price for LoveBiome? - The cash transaction price for LoveBiome was $3.7 million, with future earnouts based on revenue targets [23] Question: What impacted the reduction in cash on the balance sheet? - The reduction was primarily due to the cash transaction for LoveBiome, timing of accrued payables, and stock-based compensation settlements [24] Question: What are the marketing plans for MindBody as the weight loss season approaches? - The company initiated a go-to-market strategy with a 20% discount and events to engage customers and consultants [26][27] Question: How did LoveBiome impact consultant and customer numbers? - LoveBiome contributed $4 million in product revenue, but specific consultant numbers were not disclosed [30] Question: What are the expectations for revenue in the second half of the year? - The company anticipates a stabilization in MindBody trends and expects Q4 to have a higher proportion of revenue compared to Q3 [51][53]

Financial Data and Key Metrics Changes - For Q2 fiscal 2026, the company reported net revenue of $48.9 million, down 27.8% from $67.8 million in Q2 fiscal 2025, but up 2.9% sequentially from Q1 [13] - The gross profit percentage decreased to 74% from 80.5% in the prior year, primarily due to a one-time inventory obsolescence allowance [15] - GAAP net income was $0.3 million, or $0.02 per diluted share, compared to $2.6 million, or $0.19 per diluted share in the prior year [17] Business Line Data and Key Metrics Changes - Sales of the MindBody GLP-1 System decreased by $16.2 million compared to the prior year, significantly impacting overall revenue [14] - The LoveBiome product line contributed $4.1 million in revenue following the acquisition [14] - The decline in total active accounts was 25.2% in the Americas and 6.5% in Asia-Pacific and Europe, reflecting a decrease in the active customer base [15] Market Data and Key Metrics Changes - Revenue in the Americas decreased 32.6% to $38.5 million, while revenue in Asia-Pacific and Europe decreased 2.1% to $10.4 million [15] - The company noted a slight revenue increase in Japan on a constant currency basis [15] Company Strategy and Development Direction - The company is focused on stabilizing the GLP-1 business and exploring cost reduction opportunities to maintain profitability [5] - The integration of LoveBiome is expected to drive product diversification and market growth, with new product launches planned [8] - The company is committed to enhancing e-commerce capabilities through a partnership with Shopify, aiming to improve customer experience and conversion rates [10][40] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that Q2 performance did not meet expectations but expressed optimism about long-term growth in the health and wellness ecosystem [4] - The company expects revenue for fiscal 2026 to be in the range of $185 million to $200 million, with adjusted EBITDA of $15 million to $19 million [19] - Management emphasized the importance of natural solutions in the GLP-1 market, believing there is still significant demand for their products [47] Other Important Information - The company announced a new $60 million share repurchase program and a quarterly cash dividend of $0.045 per share [18][19] - The CEO announced plans for retirement in April 2026, with a succession plan in place to ensure leadership continuity [20] Q&A Session Summary Question: What was the cash transaction price for LoveBiome? - The cash transaction price related to LoveBiome was $3.7 million, structured in two components: a cash down payment and a future earnout based on revenue targets [23] Question: What impacted the reduction in cash on the balance sheet? - The reduction was primarily due to the cash transaction for LoveBiome, timing of accrued payables, and cash utilized for stock-based compensation [24] Question: What are the marketing plans for MindBody entering the weight loss season? - The company initiated a go-to-market strategy with a 20% discount on MindBody products and introduced a new app feature for tracking calories and activities [26][28] Question: How did LoveBiome impact consultant and customer numbers? - LoveBiome contributed $4 million in product revenue, but specific numbers on active consultants were not disclosed [30] Question: What is the revenue outlook for the second half of the year? - Management anticipates stabilization in MindBody trends and expects Q4 to have a higher proportion of revenue compared to Q3 [52]